Unique ID issued by UMIN | UMIN000040341 |
---|---|
Receipt number | R000046023 |
Scientific Title | Immunological efficacy of Qing Fei Pai Du Tang for COVID-19: an open-label, single-arm trial |
Date of disclosure of the study information | 2020/05/09 |
Last modified on | 2021/09/11 05:23:45 |
Immunological efficacy of Qing Fei Pai Du Tang for COVID-19
COVID-19/Qing Fei Pai Du Tang
Immunological efficacy of Qing Fei Pai Du Tang for COVID-19: an open-label, single-arm trial
COVID-19/Qing Fei Pai Du Tang
Japan |
COVID-19
Pneumology | Infectious disease |
Others
NO
A rapid increase in the numbers of patients with and deaths from COVID-19 is becoming a global threat to public health. One of the reasons for the current pandemic is that effective vaccine or specific drugs against COVID-19 remain unavailable. In China, traditional Chinese herbal medicine has been integrated into the official therapeutic protocols against COVID-19. The Qing Fei Pai Du Tang (QFPDT) is a Chinese multi-herbal formula newly developed and optimized specifically for patients with COVID-19. Recent clinical trials in China have demonstrated that the QFPDT successfully alleviates COVID-19 symptoms in a large number of mild to critical cases. However, the underlying pharmacological mechanism and the feasibility of prophylactic use in uninfected individuals remain unknown. We thus examine whether hematological and immunological parameters of healthy individuals are affected by the low-dose administration of QFPDT.
Efficacy
Plasma cytokine levels after administration of Qing Fei Pai Du Tang for 3 days
Hematology and blood biochemistry after administration of Qing Fei Pai Du Tang for 3 days
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Prevention
Medicine |
We reduce the dose of each herb to 1/30 to explore the feasibility of prophylactic use. The QFPDT decoction is prepared by boiling the mixed herbs in 600 ml of water for 1 h and divided into six aliquots. The subjects are instructed to take the aliquot of the decoction orally 40 min after each breakfast and dinner for 3 days.
20 | years-old | <= |
70 | years-old | > |
Male and Female
Healthy volunteers
Current infectious, inflammatory, or immune-related diseases
15
1st name | Tsutomu |
Middle name | |
Last name | Nakamura |
Institute for Quantitative Biosciences, The University of Tokyo
Laboratory of Molecular and Genetic Information
113-0032
1-1-1, Yayoi, Bunkyo-ku, Tokyo
03-5841-7834
nakamurachibiko@gmail.com
1st name | Tomoka |
Middle name | |
Last name | Ebisui |
Takanawa Clinic
Administration Department
140-0001
1-22-17, Kitashinagawa, Shinagawa-ku, Tokyo
03-6433-3165
jimukyoku@takanawa-clinic.com
Administration Department, Takanawa Clinic
Administration Department, Takanawa Clinic
Self funding
Research Ethics Committee of Takanawa Clinic
1-22-17, Kitashinagawa, Shinagawa-ku, Tokyo
03-6712-9747
support@idou-medical.jp
NO
高輪クリニック(東京都)
2020 | Year | 05 | Month | 09 | Day |
Unpublished
18
Completed
2020 | Year | 04 | Month | 20 | Day |
2020 | Year | 05 | Month | 07 | Day |
2020 | Year | 05 | Month | 09 | Day |
2020 | Year | 05 | Month | 16 | Day |
2020 | Year | 05 | Month | 08 | Day |
2021 | Year | 09 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046023
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |